Latest Iridocyclitis Stories
An implant that releases the medication dexamethasone within the eye appears safe and effective for the treatment of some types of uveitis (swelling and inflammation in the eye's middle layer).
Application Includes Data from a Comparative Trial in Anterior Uveitis TAMPA, Fla., March 16 /PRNewswire/ -- Sirion Therapeutics, Inc. announced today that its supplemental New Drug Application (sNDA) submitted to the U.S.
New Clinical Advisory Board Established to Provide Industry Leadership and Ophthalmology Experience ZURICH, Switzerland, Feb.
TAMPA, Fla., Nov.
TAMPA, Fla., Oct.
TAMPA, Fla., Oct. 6 /PRNewswire/ -- Sirion Therapeutics, Inc., a privately held ophthalmic-focused biopharmaceutical company, announced today that Durezol(TM) (difluprednate ophthalmic emulsion) 0.05% is now commercially available. Durezol, which was approved by the U.S.
EyeGate Pharma, a privately held specialty pharmaceutical company using iontophoresis technology to safely and non-invasively deliver therapeutics into the front and back of the eye to treat serious ocular diseases, today announced the initiation of patient dosing in a prospective, multi-center, randomized, double-masked U.S.
Lux Biosciences today announced the completion of enrollment for the landmark LUMINATE (Luveniq Uveitis Multicenter Investigation of a New Approach to TrEatment) pivotal clinical trial program, which is investigating the use of LUVENIQ(TM) (voclosporin; previously designated LX211) as a corticosteroid-sparing agent for the treatment of patients with non-infectious uveitis.
- The horn of a unicorn considered as a medical or pharmacological ingredient.
- A winged horse with a single horn on its head; a winged unicorn.